Attexis Digital Therapy Reduces ADHD Symptoms in Adults: RCT Results

A new randomized controlled trial offers encouraging news for adults living with Attention-Deficit/Hyperactivity Disorder (ADHD). The study, published in Psychological Medicine, demonstrates that the digital therapy program “attexis” leads to a significant and clinically relevant reduction in ADHD symptoms. This finding arrives as access to traditional ADHD care remains a challenge for many, with often lengthy wait times for specialist appointments.

Understanding attexis and its Approach

attexis is a self-guided online intervention rooted in principles of cognitive-behavioral therapy (CBT) and mindfulness. Developed to support adults diagnosed with ADHD, it aims to provide accessible and flexible support, whether or not individuals are also undergoing medication treatment. The program, comprised of six interactive digital therapeutic dialogues, personalizes content based on initial user responses and ongoing selections. This tailored approach focuses on practical skills like daily structuring, symptom management, and bolstering self-management abilities – all aligned with established S3 treatment guidelines as outlined by MEDICE, the company behind attexis.

The core of attexis lies in its ability to adapt to individual needs. Users aren’t presented with a rigid program; instead, the dialogues evolve based on their answers, ensuring the content remains relevant to their specific challenges. Weekly reflections and progress overviews are incorporated to help users visualize their development and maintain motivation. The program also includes practical tools like planning aids, checklists, and routines designed to translate therapeutic concepts into everyday life.

The Trial: Design and Key Findings

The recent randomized controlled trial, led by Roberto D’Amelio and colleagues, investigated the effectiveness of attexis in a real-world setting. The study involved adults with ADHD who were randomly assigned to either receive the attexis intervention or a control condition. Researchers assessed ADHD symptoms using standardized measures before, during, and after the intervention period. The results indicated a statistically significant and clinically meaningful reduction in ADHD symptoms among participants who used attexis compared to those in the control group. Details of the trial are available as a pre-print on medRxiv.

While the full details of the study’s methodology, including sample size and specific assessment tools, are available in the published pre-print, it’s important to note that this is an initial publication. Further peer review and validation will be crucial to confirm these findings. The researchers emphasize that attexis is intended to be used as a supplement to, not a replacement for, traditional ADHD treatment, including medication and psychotherapy.

What Does “Clinically Relevant” Mean?

The term “clinically relevant” is crucial here. It doesn’t simply mean a statistically significant difference was observed; it means the observed reduction in symptoms was large enough to be noticeable and impactful in the lives of the participants. In other words, the improvement wasn’t just a small, statistically-driven effect, but a change that individuals likely experienced as a genuine benefit.

Access and Coverage in Europe

The availability of attexis is currently focused in Europe. As of August 6, 2025, the program is covered by statutory health insurers and many private insurers, making it a more accessible option for adults with ADHD. MEDICE, the developer, highlights this as a significant step towards expanding treatment options, particularly given the often-lengthy wait times for traditional therapy.

ADHD in Adults: A Growing Area of Focus

ADHD is often considered a childhood condition, but it frequently persists into adulthood, affecting an estimated 2.5% of adults globally. Symptoms in adults can manifest differently than in children, often presenting as difficulty with organization, time management, impulsivity, and emotional regulation. These challenges can significantly impact various aspects of life, including work, relationships, and overall well-being. The increasing recognition of adult ADHD has led to a growing demand for effective and accessible treatment options.

Limitations and Future Directions

It’s important to approach these findings with a balanced perspective. The current study, while promising, has limitations inherent to its design. Further research is needed to confirm these results in larger and more diverse populations. Long-term follow-up studies are also essential to assess the durability of the observed benefits. Research should explore the optimal ways to integrate attexis into existing ADHD treatment pathways.

The study authors and MEDICE are actively pursuing further research to refine and expand the application of attexis. This includes investigating its effectiveness in combination with other therapies and exploring its potential to address specific ADHD subtypes. The goal is to continue improving the program’s ability to provide personalized and effective support for adults with ADHD.

Looking ahead, the broader field of digital mental health is poised for continued growth. As technology advances and more evidence-based digital interventions become available, People can expect to witness a greater emphasis on accessible and personalized mental healthcare solutions. The success of programs like attexis could pave the way for similar innovations in the treatment of other mental health conditions.